Cheaper generic Ozempic is coming soon — but not for AmericansCheaper generic Ozempic is coming soon — but not for Americans
India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic?
Continuing tirzepatide at full dose helps preserve weight loss over 112 weeksContinuing tirzepatide at full dose helps preserve weight loss over 112 weeks
New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated dose (MTD) of tirzepatide are seven times more likely to maintain that weight loss by continuing on MTD than those who stop treatment, Read More
A 13-gene panel may help predict response to chemotherapy in triple-negative breast cancerA 13-gene panel may help predict response to chemotherapy in triple-negative breast cancer
Researchers at The University of Texas MD Anderson Cancer Center have characterized cancer cell-specific features in the tumor microenvironment (TME) of early-stage triple-negative breast cancer (TNBC) tissues, identifying specific macrophage subtypes associated with chemotherapy response.
How do weight-loss drugs like Mounjaro and Wegovy work?How do weight-loss drugs like Mounjaro and Wegovy work?
Wegovy and Mounjaro are available to certain patients on the NHS, and can also be bought privately. Wegovy and Mounjaro are available to certain patients on the NHS, and can also be bought privately.
Study on GLP-1s and Breast Cancer ‘Too Good to Be True’?Study on GLP-1s and Breast Cancer ‘Too Good to Be True’?
(MedPage Today) — Use of GLP-1 receptor agonists in breast cancer patients was linked to lower mortality and recurrence risk in a retrospective study, but experts are questioning the quality of the underlying data. At 10 years, the risk of all… (MedPage Today) — Use of GLP-1 receptor agonists in breast cancer patients was Read More
Metastatic Breast Cancers on the Rise, U.S. Study ShowsMetastatic Breast Cancers on the Rise, U.S. Study Shows
(MedPage Today) — Despite improvements in survival, the incidence of stage IV breast cancer increased significantly from 2010 through 2021, according to a U.S. population-based cohort study.
The age-adjusted incidence rate of de novo stage IV…
FTC Blocked From Endocrine Society Probe; FDA-Tzield Drama; GLP-1 Gene Therapy?FTC Blocked From Endocrine Society Probe; FDA-Tzield Drama; GLP-1 Gene Therapy?
(MedPage Today) — A federal judge blocked the Federal Trade Commission (FTC) from investigating the Endocrine Society and World Professional Association for Transgender Health, which support gender-affirming care in minors. (Reuters via… (MedPage Today) — A federal judge blocked the Federal Trade Commission (FTC) from investigating the Endocrine Society and World Professional Association for Read More
FDA clears ArteraAI Breast for breast cancer risk stratificationFDA clears ArteraAI Breast for breast cancer risk stratification
The U.S. Food and Drug Administration has cleared ArteraAI Breast for use in patients with early-stage, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer.
STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! Today, my colleagues Isabella Cueto and Lev Facher are launching the Deadliest Drug, a series on the often ignored Read More
FDA Approves GLP-1 Obesity Pill Without Food or Water RestrictionsFDA Approves GLP-1 Obesity Pill Without Food or Water Restrictions
The US Food and Drug Administration (FDA) approved the oral glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron, marketed as Foundayo, for daily use in people with overweight or obesity. Unlike other oral GLP-1 drugs, orforglipron can be taken any time of day without food or water restrictions. The US Food and Drug Administration (FDA) approved the Read More